February 22, 2022 TargED raises €39 million in a series A investment round

Drugs designed to effectively treat all types of thrombosis

What is TargED?

TargED Biopharmaceuticals B.V. is a Netherlands based biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED’s name stands for Targeted Enzyme Delivery and the company’s unique biological drugs use small antibodies (‘VHH’) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

More about us

Why we do what we do


Thrombosis is one of the leading causes of death worldwide, accounting for over 16 million deaths per year.


We are developing TGD001: a targeted, localized thrombolytic designed to effectively treat all types of thrombotic disorders.


Our goal is to improve the lives of patients suffering from thrombosis.

Our team

What is TGD001?

TargED’s lead compound is TGD001. In preclinical models, it has shown effective thrombolysis, the breakdown of blood clots, for various forms of thrombosis. It is currently preclinically validated in two thrombotic indications: Immune Thrombotic Thrombocytopenic Purpura (iTTP – an orphan indication) and Acute Ischemic Stroke (AIS). The ambition is to accelerate thrombolysis in patients with all forms of thrombosis, irrespective of the composition of the blood clot, or thrombus.

More about TGD001